**Table S1. Primers for microRNA genes for qRT-PCR analysis**

|  |  |  |
| --- | --- | --- |
| Target gene | Primer sequence (5’ 3’) | miRBase accession code |
| miR-16 | TAGCAGCACGTAAATATTGGCG | MIMAT0000069 |
| miR-103a | AGCAGCATTGTACAGGGCTATGA | MIMAT0000101 |
| let-7e | GGGTGAGGTAGGAGGTTGTAT | MI0000066 |
| miR-30b | GGGTGTAAACATCCTACACTCA | MIMAT0000420 |
| miR-30e  | CTTTCAGCGGATGTTTACAGC |  MI0000091 |
| miR-33a | GGGGTCATTGTAGTTGC  | MIMAT0000693 |
| miR-150 | TCTCCCAACCCTTGTACCAGTG | MIMAT0000451 |

**Table S2. Primers for microRNA target genes for qRT-PCR analysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Target genes | Forward primer (5’🡪3’) | Reverse primer (5’🡪3’) | NCBI accession code | Publications |
| GAPDH | TGCACCACCAACTGCTTAGC | GGCATGGACTGTGGTCATGAG | NM\_002046.6 | McCurdy, D. et al. (2008) ‘Validation of the comparative quantification method of real-time PCR analysis and a cautionary tale of housekeeping gene selection’, Gene Ther Mol Biol, 12, pp.15-24. |
| EZH2 | CCCTGACCTCTGTCTTACTTGTGGA | ACGTCAGATGGTGCCAGCAATA | XM\_017011817.2 | Fujii, S. et al. (2008) ‘Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation’, J Biol Chem, 283(25), pp. 17324–17332. doi: 10.1074/jbc.M800224200. |
| DNMT3A | TATTGATGAGCGCACAAGAGAGC | GGGTGTTCCAGGGTAACATTGAG | NM\_175629.2 | Qiu X. et al. (2010) ‘Epigenetic activation of E-cadherin is a candidate therapeutic target in human hepatocellular carcinoma’, Exp Ther Med, 1(3), Pp. 519–523. doi: 10.3892/etm\_00000082. |
| ABCA1 | AACAGTTTGTGGCCCTTTTG | AGTTCCAGGCTGGGGTACTT | NM\_005502.3 | Sporstøl, M. et al. (2007) ‘ABCA1, ABCG1 and SR-BI: hormonal regulation in primary rat hepatocytes and human cell lines’, BMC Mol Biol, 8(5). doi: 10.1186/1471-2199-8-5. |
| RIP140 | TGGGGAAGTGTTTGGATTGT | TGTGCATCTTCTGGCTGTG | NM\_003489.3 | Not applicable |

**Table S3. AST, ALT and HCT of patients from admission to discharge**

|  |  |
| --- | --- |
| **AST level (U/L), [n]** | P value  |
| Days from fever onset | DF | SD |  |
| At admission | 45.0±16.0, [20] | 61.0±24.5, [20] | 0.44 |
| Day 5 | 73.0±44.0, [9] | 57.5±8.0, [5] | 0.65 |
| Day 6 | 68.5±14.5, [6] | 142.0±0.0, [3] | 0.16 |
| Day 7 | 185.5±42.5, [2] | 115.0±14.2, [2] | 0.63 |
| Day 8 | 417.5±226.5, [2] | 160.0±38.0, [6] | 0.09 |
| Day 5 to 8 | 116.0±52.0, [10] | 142.0±38.0, [11] | 0.61 |
| **ALT level, (U/L), [n]** |  |
| Days from fever onset | DF | SD |  |
| At admission | 33.0±14.0, [20] | 47.0±15.0, [20] | 0.44 |
| Day 5 | 53.0±21.5, [8] | 41.7±15.7, [5] | 0.53 |
| Day 6 | 67.0±17.0, [7] | 71.0±9.0, [3] | 0.75 |
| Day 7 | 116.0±57.0, [3] | 80.2±56.1, [3] | 0.38 |
| Day 8 | 212.6±0.0, [1] | 105.5±7.0, [6] | 0.13 |
| Day 5 to 8 | 72.0±28.0, [11] | 100.5±24.0, [12] | 0.71 |
| **HCT (%), [n]** |
| Days from fever onset | DF | SD |  |
| At admission | 40.0±2.2, [14] | 39.8±2.8, [17]b | 0.30 |
| Day 5 | 36.0±5.3, [3] | 45.9±4.3, [7]a | 0.08 |
| Day 6 | 36.4±4.8, [2] | 39.5±4.2, [3] | 0.27 |
| Day 7 | 41.5±1.8, [4] | 43.6±1.4, [3] | 0.49 |
| Day 8 | 47.0±0.0, [1] | 44.6±3.3, [3] | 0.54 |
| Day 5 to 8 | 41.5±8.6, [7] | 43.6±3.5, [9]b | 0.57 |

AST and ALT levels (Median±MAD) for [n] number of patients and HCT % (Median±MAD) (P<0.05 considered as a statistically significant difference using Mann-Whitney U test). Significant differences between at admission and on day 5 and at admission and day 5 to 8 marked by a, b down the column (P<0.05 considered as a statistically significant difference using paired t – test).

**Table S4. Relative expression of microRNA at admission**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| miRNA  | Days from fever onset | 2- **ΔΔ**Cq (log2) | Mean **Δ**Cq ±SEM | P values |
| DF | SD |
| let-7e | Day 2 | 2.15 | 5.54±1.36 | 5.06±0.70 | 0.74 |  |
| Day 3 | -1.84 | 4.81±0.58 | 5.65±0.72 | 0.53 |  |
| Day 4 | 1.30 | 5.58±0.38 | 4.43±0.71 | 0.14 |  |
| Within 3 days | -0.79 | 5.05±0.46 | 5.57±0.60 | 0.27 |  |
| Within 4 days | 0.24 | 5.34±0.27 | 5.27±0.50 | 0.91 |  |
| miR-30b | Day 2 | 1.42 | 10.89±0.91 | 9.46±1.52 | 0.54 |
| Day 3 | -0.40 | 10.18±1.08 | 10.57±0.60 | 0.74 |
| Day 4 | 0.28 | 9.85±0.64 | 9.60±0.71 | 0.81 |
| Within 3 days | 0.01 | 10.36±0.82 | 10.35±0.55 | 0.99 |
| Within 4 days | 0.04 | 10.19±0.47 | 10.16±0.45 | 0.96 |
| miR-30e | Day 2 | 0.69 | 14.36±0.83 | 13.67±0.34 | 0.49 |
| Day 3 | 1.30 | 15.57±1.01 | 14.26±0.59 | 0.25 |
| Day 4 | -0.22 | 14.55±0.85 | 14.79±0.67 | 0.86 |
| Within 3 days | 1.12 | 15.26±0.78 | 14.14±0.48 | 0.21 |
| Within 4 days | 0.36 | 14.66±0.54 | 14.30±0.39 | 0.60 |
| miR-33a | Day 2 | 1.82 | 15.25±0.32 | 13.42±2.65 | 0.53 |
| Day 3 | 1.69 | 17.77±1.10 | 16.08±1.09 | 0.35 |
| Day 4 | -2.06 | 16.63±0.92 | 18.69±1.36 | 0.23 |
| Within 3 days | 1.59 | 17.14±0.91 | 15.55±1.02 | 0.32 |
| Within 4 days | 0.25 | 16.58±0.62 | 16.33±0.87 | 0.82 |
| miR-150 | Day 2 | 0.06 | 7.35±0.45 | 7.30±1.45 | 0.98 |
| Day 3 | 4.04 | 9.68±0.86 | 5.64±0.65 | 0.00\* |
| Day 4 | -0.38 | 8.42±0.91 | 8.83±1.44 | 0.81 |
| Within 3 days | 3.13 | 9.10±0.74 | 5.97±0.60 | 0.00\* |
| Within 4 days | 1.76 | 8.55±0.59 | 6.68±0.62 | 0.04 |

Relative expression of microRNA presented as fold change based on 2-ΔΔCq values against miR-16 and miR-103a (log2) and **Δ**Cq at 95% confidence intervals (CI). \* P<0.01 considered as statistical significant differential expression based on ΔCq ± SEM using independent t – test with Bonferroni adjustment**.**

**Table S5.** **Relative expression of putative target genes of microRNA at admission**

Relative expression presented as fold change based on 2-ΔΔCq values against GAPDH (log2) and **Δ**Cq at 95% confidence intervals (CI). \* P<0.01 considered as statistical significant differential expression based on ΔCq ± SEM using independent t – test with Bonferroni adjustment**.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Putative target genes | Days from fever onset | 2- **ΔΔ**Cq(log2) | Mean **Δ**Cq±SEM  | P values |
| DF | SD |
| EZH2 | Day 2 | 0.83 | 3.40±0.81 | 2.57±1.51 | 0.76 |  |
| Day 3 | -2.18 | 3.39±0.81 | 4.78±0.67 | 0.07 |  |
| Day 4 | -2.74 | 1.31±0.56 | 4.06±0.38 |  0.01\* |  |
| Within 3 days | -1.51 | 2.81±0.51 | 4.33±0.68 | 0.12 |  |
| Day 3 & day 4 | -2.86 | 1.70±0.45 | 4.57±0.51 |  0.00\* |  |
| Within 4 days | -2.06 | 2.20±0.44 | 4.26±0.51 |  0.00\* |  |
| DNMT3A | Day 2 | -0.15 | 4.24±1.09 | 3.85±0.29 | 0.96 |  |
| Day 3 | 0.89 | 3.55±0.99 | 4.55±0.62 | 0.90 |  |
| Day 4 | -1.29 | 2.86±0.47 | 3.60±0.34 | 0.30 |  |
| Within 3 days | 0.30 | 3.75±0.74 | 4.41±0.53 | 0.90 |  |
| Day 3 & day 4 | -0.57 | 3.09±0.45 | 4.27±0.50 | 0.51 |  |
| Within 4 days | -0.04 | 3.36±0.39 | 4.20±0.43 | 0.62 |
| ABCA1 | Day 2 | 0.39 | 1.20±1.61 | 1.35±1.46 | 0.69 |
| Day 3 | -1.00 | 3.71±1.27 | 3.55±0.63 | 0.39 |
| Day 4 | -0.58 | 2.65±0.52 | 3.66±0.88 | 0.31 |
| Within 3 days | 0.56 | 2.87±1.05 | 3.04±0.77 | 0.48 |
| Day 3 & day 4 | -1.18 | 3.09±0.56 | 3.58±0.66 | 0.09 |
| Within 4 days | -0.79 | 2.75±0.54 | 3.15±0.62 | 0.16 |
| RIP140 | Day 2 | -0.07 | -0.99±2.48 | -0.91±2.57 | 0.99 |
| Day 3 | -1.51 | 1.16±1.11 | 2.70±0.82 | 0.31 |
| Day 4 | -0.92 | 1.47±0.67 | 1.79±1.35 | 0.81 |
| Within 3 days | -0.43 | 0.55±1.02 | 1.98±0.70 | 0.27 |
| Day 3 & day 4 | -1.07 | 1.36±0.56 | 2.43±0.74 | 0.28 |
| Within 4 days | -0.92 | 1.36±0.55 | 1.92±0.74 | 0.54 |